INSPIRING FUTURES

A candidate H1N1 pandemic influenza vaccine elicits protective Immunity in mice.

Jacobson, Steven, Steitz, Julia, Barlow, Peter G, Hossain, M Jaber, Kim, Eun, Okada, Kaori, Kenniston, Tom, Rea, Sheri, Donis, Ruben O and Gambotto, Andrea (2010) A candidate H1N1 pandemic influenza vaccine elicits protective Immunity in mice. PLoS ONE, 5 (5). e10492. ISSN 1932-6203

[img]
Preview
PDF
Available under License Creative Commons Attribution Non-commercial.

Download (345kB) | Preview

    Abstract/Description

    Background
    In 2009 a new pandemic disease appeared and spread globally. The recent emergence of the pandemic influenza virus H1N1 first isolated in Mexico and USA raised concerns about vaccine availability. We here report our development of an adenovirus-based influenza H1N1 vaccine tested for immunogenicity and efficacy to confer protection in animal model.

    Methods
    We generated two adenovirus(Ad5)-based influenza vaccine candidates encoding the wildtype or a codon-optimized hemagglutinin antigen (HA) from the recently emerged swine influenza isolate A/California/04/2009 (H1N1)pdm. After verification of antigen expression, immunogenicity of the vaccine candidates were tested in a mouse model using dose escalations for subcutaneous immunization. Sera of immunized animals were tested in microneutalization and hemagglutination inhibition assays for the presence of HA-specific antibodies. HA-specific T-cells were measured in IFNγ Elispot assays. The efficiency of the influenza vaccine candidates were evaluated in a challenge model by measuring viral titer in lung and nasal turbinate 3 days after inoculation of a homologous H1N1 virus.

    Conclusions/Significance
    A single immunization resulted in robust cellular and humoral immune response. Remarkably, the intensity of the immune response was substantially enhanced with codon-optimized antigen, indicating the benefit of manipulating the genetic code of HA antigens in the context of recombinant influenza vaccine design. These results highlight the value of advanced technologies in vaccine development and deployment in response to infections with pandemic potential. Our study emphasizes the potential of an adenoviral-based influenza vaccine platform with the benefits of speed of manufacture and efficacy of a single dose immunization

    Item Type: Article
    Print ISSN: 1932-6203
    Uncontrolled Keywords: Influenza virus H1N1; vaccines; immunogenicity; immune response;
    University Divisions/Research Centres: Faculty of Health, Life & Social Sciences > School of Health and Social Sciences
    Dewey Decimal Subjects: 600 Technology > 610 Medicine & health > 616 Diseases > 616.2 Respiratory diseases
    Library of Congress Subjects: R Medicine > RF Otorhinolaryngology
    Item ID: 5173
    Depositing User: Mrs Lyn Gibson
    Date Deposited: 27 Mar 2012 12:18
    Last Modified: 18 Jun 2012 14:29
    URI: http://researchrepository.napier.ac.uk/id/eprint/5173

    Actions (login required)

    View Item

    Document Downloads

    More statistics for this item...

    Edinburgh Napier University is a registered Scottish charity. Registration number SC018373